• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比利时大学医院中毛霉菌病发病率的增加。

Increasing incidence of mucormycosis in University Hospital, Belgium.

机构信息

Leuven University Hospitals, Leuven, Belgium.

出版信息

Emerg Infect Dis. 2010 Sep;16(9):1456-8. doi: 10.3201/eid1609.100276.

DOI:10.3201/eid1609.100276
PMID:20735932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3294978/
Abstract

To determine why incidence of mucormycosis infections was increasing in a large university hospital in Belgium, we examined case data from 2000-2009. We found the increase was not related to voriconazole use but most probably to an increase in high-risk patients, particularly those with underlying hematologic malignancies.

摘要

为了确定为什么比利时一家大型大学医院的毛霉菌病感染发病率正在上升，我们检查了 2000 年至 2009 年的病例数据。我们发现这种增加与伏立康唑的使用无关，但很可能与高危患者，特别是患有潜在血液恶性肿瘤的患者的增加有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4e/3294978/546cb133ea12/10-0276-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4e/3294978/aff6a93b1e8f/10-0276-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4e/3294978/546cb133ea12/10-0276-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4e/3294978/aff6a93b1e8f/10-0276-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4e/3294978/546cb133ea12/10-0276-F2.jpg

相似文献

1
Increasing incidence of mucormycosis in University Hospital, Belgium.比利时大学医院中毛霉菌病发病率的增加。
Emerg Infect Dis. 2010 Sep;16(9):1456-8. doi: 10.3201/eid1609.100276.
2
Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?伏立康唑相关的接合菌病：不断演变的抗真菌预防和免疫抑制措施的一个重大后果？
Clin Microbiol Infect. 2009 Oct;15 Suppl 5:93-7. doi: 10.1111/j.1469-0691.2009.02988.x.
3
[Mucormycosis: retrospective evaluation of 12 cases].[毛霉菌病：12例回顾性评估]
Mikrobiyol Bul. 2011 Jul;45(3):504-11.
4
[Breakthrough pulmonary mucormycosis during voriconazole treatment after reduced-intensity cord blood transplantation for a patient with acute myeloid leukemia].[急性髓系白血病患者在减低强度脐血移植后伏立康唑治疗期间发生的突破性肺毛霉病]
Rinsho Ketsueki. 2007 May;48(5):412-7.
5
Mucormycosis in hematologic patients.血液系统疾病患者的毛霉病
Haematologica. 2004 Feb;89(2):207-14.
6
Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.
Leuk Lymphoma. 2004 Oct;45(10):2161-3. doi: 10.1080/10428190410001700803.
7
Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.伏立康唑预先暴露选择突破烟曲霉-根霉混合模型的肺部感染的毛霉病。
Virulence. 2011 Jul-Aug;2(4):348-55. doi: 10.4161/viru.2.4.17074. Epub 2011 Jul 1.
8
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.伏立康唑相关严重不良事件：治疗药物监测在韩国患者中的临床应用。
Int J Infect Dis. 2011 Nov;15(11):e753-8. doi: 10.1016/j.ijid.2011.06.004. Epub 2011 Aug 9.
9
Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.比较伏立康唑与泊沙康唑预防血液恶性肿瘤高危患者侵袭性真菌感染的安全性和有效性。
Int J Antimicrob Agents. 2017 Sep;50(3):384-388. doi: 10.1016/j.ijantimicag.2017.03.021. Epub 2017 Jul 8.
10
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.伏立康唑治疗儿童曲霉病、赛多孢子菌病及其他侵袭性真菌感染
Pediatr Infect Dis J. 2002 Mar;21(3):240-8. doi: 10.1097/00006454-200203000-00015.

引用本文的文献

1
Ten-Year Experience on 601 Patients with Mucormycosis at Eight Tertiary Care Centers in Iran.伊朗八家三级医疗中心对601例毛霉菌病患者的十年经验
Mycopathologia. 2025 Sep 17;190(5):87. doi: 10.1007/s11046-025-00995-x.
2
Treatment and Survival Outcomes in Rhino-Orbital Mucormycosis with and without Orbital Exenteration: A Retrospective Case Series and Literature Review.有或无眼眶内容剜除术的鼻眶毛霉菌病的治疗及生存结果：一项回顾性病例系列研究及文献综述
Int Med Case Rep J. 2025 Jun 24;18:747-762. doi: 10.2147/IMCRJ.S530233. eCollection 2025.
3
Development and evaluation of a Pan-Mucorales Real-time PCR and a multiplex Real-time PCR for detection and identification of , and spp. in clinical specimens.

本文引用的文献

1
Forty-one recent cases of invasive zygomycosis from a global clinical registry.全球临床注册中心的 41 例侵袭性接合菌病近期病例。
J Antimicrob Chemother. 2010 Feb;65(2):296-302. doi: 10.1093/jac/dkp430. Epub 2009 Dec 11.
2
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.法国 1997-2006 年接合菌病（毛霉病）发病率上升。
Emerg Infect Dis. 2009 Sep;15(9):1395-401. doi: 10.3201/eid1509.090334.
3
Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
用于临床标本中毛霉目、根霉属、毛霉属和犁头霉属检测与鉴定的泛毛霉目实时荧光定量PCR及多重实时荧光定量PCR的开发与评估
J Clin Microbiol. 2025 Jun 11;63(6):e0193724. doi: 10.1128/jcm.01937-24. Epub 2025 Apr 30.
4
Mucormycosis in a Diabetic Patient: A Case Report From Georgia.一名糖尿病患者的毛霉菌病：来自佐治亚州的病例报告
Cureus. 2024 Sep 14;16(9):e69399. doi: 10.7759/cureus.69399. eCollection 2024 Sep.
5
Mucormycosis: A Rare disease to Notifiable Disease.毛霉菌病：一种罕见但应报告的疾病。
Braz J Microbiol. 2024 Jun;55(2):1065-1081. doi: 10.1007/s42770-024-01315-z. Epub 2024 Apr 1.
6
H3K4 methylation regulates development, DNA repair, and virulence in Mucorales.H3K4甲基化调控毛霉目真菌的发育、DNA修复及毒力。
IMA Fungus. 2024 Mar 14;15(1):6. doi: 10.1186/s43008-023-00136-3.
7
Rapid detection of Mucorales based on recombinase polymerase amplification and real-time PCR.基于重组酶聚合酶扩增和实时荧光定量PCR的毛霉目快速检测
Front Microbiol. 2023 Oct 20;14:1273073. doi: 10.3389/fmicb.2023.1273073. eCollection 2023.
8
Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review.《COVID-19 大流行期间的毛霉菌病及其激增：最新综述》。
Curr Microbiol. 2023 Aug 17;80(10):322. doi: 10.1007/s00284-023-03430-w.
9
Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports.希腊毛霉病的流行病学；一项全国性前瞻性调查及已发表病例报告的结果
J Fungi (Basel). 2023 Mar 29;9(4):425. doi: 10.3390/jof9040425.
10
What Is New in Pulmonary Mucormycosis?肺毛霉病有哪些新进展？
J Fungi (Basel). 2023 Feb 28;9(3):307. doi: 10.3390/jof9030307.
伏立康唑相关的接合菌病：不断演变的抗真菌预防和免疫抑制措施的一个重大后果？
Clin Microbiol Infect. 2009 Oct;15 Suppl 5:93-7. doi: 10.1111/j.1469-0691.2009.02988.x.
4
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.欧洲癌症研究与治疗组织/侵袭性真菌感染合作组和美国国立过敏与传染病研究所真菌病研究组（EORTC/MSG）共识组对侵袭性真菌病的修订定义。
Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.
5
Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis.糖尿病患者中接合菌病报告病例数的减少：一种假设。
Clin Infect Dis. 2007 Apr 15;44(8):1089-90. doi: 10.1086/512817. Epub 2007 Mar 2.
6
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.毛霉菌病的流行病学与转归：929例报告病例的综述
Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29.
7
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.曲霉活性抗真菌治疗时代一家三级癌症中心的接合菌病：27例近期病例的病例对照观察研究
J Infect Dis. 2005 Apr 15;191(8):1350-60. doi: 10.1086/428780. Epub 2005 Mar 16.
8
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.造血干细胞移植受者伏立康唑治疗后发生的突破性接合菌病。
N Engl J Med. 2004 Feb 26;350(9):950-2. doi: 10.1056/NEJM200402263500923.
9
Breast cancer screening pathology: an assessment of the practise and needs in Belgium and Luxembourg.
Virchows Arch. 2000 Oct;437(4):354-9. doi: 10.1007/s004280000254.
10
The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance.1992 - 1993年旧金山湾区侵袭性真菌感染的流行病学特征：基于人群的实验室主动监测结果
Clin Infect Dis. 1998 Nov;27(5):1138-47.